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Abstract
Background: Geographical differences in patient characteristics, management and outcomes in heart 
failure (HF) trials are well recognized. The aim of this study was to assess the consistency of the treat-
ment effect of coenzyme Q10 (CoQ10) in the European sub-population of Q-SYMBIO, a randomized 
double-blind multinational trial of treatment with CoQ10, in addition to standard therapy in chronic HF.
Methods: Patients with moderate to severe HF were randomized to CoQ10 300 mg daily or placebo in 
addition to standard therapy. At 3 months the primary short-term endpoints were changes in New York 
Heart Association (NYHA) functional classification, 6-min walk test, and levels of N-terminal pro–B type  
natriuretic peptide. At 2 years the primary long-term endpoint was major adverse cardiovascular events 
(MACE). 
Results: There were no significant changes in short-term endpoints. The primary long-term endpoint 
of MACE was reached by significantly fewer patients in the CoQ10 group (n = 10, 9%) compared to the 
placebo group (n = 33, 27%, p = 0.001). The following secondary endpoints were significantly improved 
in the CoQ10 group compared with the placebo group: all-cause and cardiovascular mortality, NYHA 
classification and left ventricular ejection fraction (LVEF). In the European sub-population, when 
compared to the whole group, there was greater adherence to guideline directed therapy and similar 
results for short- and long-term endpoints. A new finding revealed a significant improvement in LVEF.
Conclusions: The therapeutic efficacy of CoQ10 demonstrated in the Q-SYMBIO study was confirmed 
in the European sub-population in terms of safely reducing MACE, all-cause mortality, cardiovascular 
mortality, hospitalization and improvement of symptoms. (Cardiol J 2019; 26, 2: 147–156)
Key words: chronic heart failure, coenzyme CoQ10, ubiquinone, randomized controlled 
trial, major adverse cardiovascular events, mortality, hospitalization
Introduction
Heart failure (HF) is a progressive worsen-
ing of cardiac function, due to a variety of causes 
including ischemic heart disease, hypertension, 
cardiomyopathy and diabetes. Despite consider-
able advances in treatment options, HF continues 
to be associated with a high symptomatic burden, 
frequent hospitalizations and a poor long-term 
prognosis with 50% of HF patients dying within 
5 years of diagnosis [1].
Coenzyme Q10 (CoQ10) is an essential compo-
nent in the production of cellular energy (ATP) in 
mitochondria. In addition, CoQ10 has strong anti-
oxidative properties that protects against cellular 
damage from free radicals including reactive oxy-
gen species [2–4]. CoQ10 is primarily synthesized 
endogenously and in sufficient amounts during 
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normal physiological conditions. However, endog-
enous production of CoQ10 declines with age and an 
actual deficiency is observed in a number of patho-
physiological conditions including HF [5–7]. The 
biochemical rationale of CoQ10 supplementation in 
HF patients is to correct a documented deficit in 
heart tissue CoQ10 that may lead to failure in mito-
chondrial bioenergetics and a compromised cellular 
antioxidant capacity of the myocardium [8–11].  
The Q-SYMBIO study, a multinational pro-
spective, randomized, double-blind trial, demon-
strated that treatment with CoQ10, in addition to 
standard therapy for patients with chronic HF, 
improved symptoms and reduced adverse cardio-
vascular events and mortality [12]. In Q-SYMBIO, 
patients with HF were enrolled from European and 
non-European (mainly Asian) centers. 
Geographic differences in patient characteris-
tics and management have the potential to affect 
the outcome of clinical trials. These differences 
have recently been analyzed and described in large 
HF trials [13–15]. For example, the Angiotensin– 
–Neprilysin Inhibition versus Enalapril in Heart 
Failure (PARADIGM) trial included patients from 
5 regions including European and Asian coun-
tries, and notable regional differences were found 
in baseline characteristics and background HF 
therapy. Furthermore, differences in event-rates 
of HF outcomes were found, however the benefit 
of angiotensin–neprilysin inhibition was consistent 
across regions [16]. 
The aim of the present study was to assess 
the consistency of the treatment effect of CoQ10 in 
a European sub-population (n = 231) of the total 
population of Q-SYMBIO (n = 420).  
Methods
The efficacy of CoQ10 in a European sub-popu-
lation (n = 231) of the Q-SYMBIO trial (n = 420) 
by post-hoc analysis of baseline characteristics 
for short-term (3 months) and long-term (2 years) 
endpoints were investigated. Patients with mod-
erate to severe HF were enrolled from 14 cent-
ers in 6 European countries (Poland, Denmark, 
Sweden, Hungary, Austria and Slovakia) and were 
randomized in parallel groups to either CoQ10 
300 mg (Ubiquinone, Pharma Nord ApS) daily 
(n = 108) or placebo (n = 123) in addition to stand-
ard HF therapy.
The short-term primary endpoints were chan-
ges in New York Heart Association (NYHA) func-
tional class, 6-min walk test (6MWT), and N-termi-
nal pro–B-type natriuretic peptide (NT-proBNP). 
The secondary short-term endpoint was the scoring 
of symptoms (dyspnea, fatigue, and change in symp-
toms) by patients on visual analogue scale (VAS). 
The primary long-term endpoint was a com-
posite of major adverse cardiovascular events 
(MACE) defined as unplanned hospitalization due 
to worsening of HF, cardiovascular death, urgent 
cardiac transplantation or mechanical support using 
time to first event analysis. Secondary long-term 
endpoints were mortality, changes in NYHA func-
tional class, NT-proBNP and echocardiography 
(left ventricular ejection fraction [LVEF] and cavity 
dimensions). 
Samples of serum were shipped to the core 
Biochemical Laboratory in Ancona, Italy and 
assayed for levels of CoQ10 by using high-per-
formance liquid chromatography with ultraviolet 
detection [17] and NT-proBNP using the Elecsys 
2010 immunoassay method (Roche Diagnostics, 
Mannheim, Germany) [18].
Statistical analysis
Descriptive analyses of baseline data were 
reported as frequencies. Percentages for categori-
cal data and for continuous data were reported as 
mean ± standard deviation or mean ± standard 
error for normally distributed data and median and 
lower upper quartile for non-normal data. Baseline 
characteristics were compared for indepedence be-
tween patient group using the Fisher exact test for 
categorical data and two-tailed t-test for continous 
data. The significance of treatment on continuous 
responses was analyzed by a linear model with each 
investigation center treated as a random intercept 
effect. The treatment effects were analyzed and 
adjusted for pre-defined confounders. A c2 test for 
independence with exact p values was calculated 
using the Fisher exact test for the evaluation of 
the treatment effect on categorical responses. 
Cumulative incidence curves for the risk of MACE, 
hospital stay for HF, total cardiovascular mortality, 
and all-cause mortality were constructed by the 
Kaplan-Meier method and were analyzed by the 
Cox proportional hazards regression model strati-
fied according to the center. The rates for adverse 
effects were compared between treatment groups 
by means of a c2 test for independence. For the 
short-term primary endpoints, the pre-specified 
objective was reached if the difference between 
the groups in all three endpoints had a p value 
< 0.05. For the primary long-term endpoint MACE, 
the pre-specified objective was reached if the dif-
ference between the groups had a p value < 0.05. 
For secondary endpoints, p values < 0.05 were 
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used to assess statistical significance. All data 
were analyzed with the statistical analysis program 
Stata/SE 11.2 for Windows (StataCorp LP, College 
Station, Texas).
Results
Baseline characteristics 
The two treatment groups of the European 
sub-population were similar regarding baseline 
characteristics except male gender, CoQ10 (83%) 
vs. placebo (71%) (p = 0.03) and systolic blood 
pressure, CoQ10 (127 mmHg) vs. placebo (121 
mmHg) (p = 0.03; Table 1). At the beginning of 
the study, an average of 90% of patients were 
classified as NYHA class III, 6% as NYHA class 
II and 6% as NYHA class IV and with an LVEF of 
33%. The two treatment groups were balanced for 
medication usage with an average of 92% patients 
receiving angiotensin-converting enzyme inhibitors 
or angiotensin receptor blockers, 88% receiving 
beta-blockers, 32% digoxin, 84% diuretics, 37% anti-
coagulants, 55% aldosterone antagonists, 57% statin 
derivatives and 26% diabetic medication (Table 1).
Changes in serum CoQ10 levels 
Changes in biochemical status were examined 
at short term (3 months) and long-term follow-up 
(2 years). After 3 months, serum CoQ10 significantly 
increased 3-fold in the CoQ10 group (p < 0.001) 
from 0.95 ± 0.08 μg/mL (mean ± SE) at baseline 
to 3.42 ± 0.21 μg/mL and was maintained during 
the study period with a level of 3.55 ± 0.34 μg/mL 
(p < 0.001) after 2 years. In the placebo group, 
there was a non-significant decrease in mean se-
rum CoQ10 from 0.90 ± 0.07 μg/mL at baseline to 
0.76 ± 0.04 μg/mL after 2 years (Table 2).
Effect on short-term endpoints 
At 3 months there was a borderline significant 
reduction in serum NT-proBNP (p = 0.052) in the 
CoQ10 group compared to baseline but not in the 
placebo group (Table 2). There were no changes 
from baseline in the specified short-term endpoints 
NYHA functional class, VAS score, 6MWT or heart 
rate in either treatment group or between groups 
(Table 3).
Effect on long-term endpoints 
The long-term primary endpoint MACE was 
reached by significantly fewer patients in the CoQ10 
group (n = 10, 9%) compared to the placebo group 
(n = 33, 27%, p = 0.001; Table 4). A significant 
risk reduction in MACE with CoQ10 compared to 
placebo was found from a Cox proportional hazards 
regression analysis stratified by center (hazard 
ratio [HR] 0.23; 95% confidence interval [CI] 
0.11–0.51; p < 0.001; Fig. 1). 
A significantly greater proportion of patients 
in the CoQ10 group improved by at least one grade 
in NYHA functional classification after 2 years 
(n = 39, 48%) compared to the placebo group (n = 19, 
25%, p = 0.003; Table 3). In the CoQ10 group there 
was a significant improvement of 6% in LVEF 
compared to baseline (p = 0.021) but there was no 
significant change in the placebo group (p = 0.234; 
Table 3). In the CoQ10 group, compared to baseline, 
serum NT-proBNP was reduced by a mean of 702 
pg/mL (28%) in the CoQ10 group and a reduction 
of 276 pg/mL (12%) in the placebo group. Neither 
of these values were significantly different from 
baseline nor were there differences between the 
two groups (Table 2). For heart rate and blood 
pressure there were no significant changes from 
baseline with treatment in either group nor were 
there any between-group differences (Table 3). 
All-cause mortality was lower in the CoQ10 
group, 10 (9%) patients vs. 24 (20%) patients in the 
placebo group, corresponding to a relative reduc-
tion of 53% (p = 0.040). Using a Cox proportional 
hazards regression analysis stratified by center re-
vealed a significant reduction in all-cause mortality 
with CoQ10 compared to placebo (HR 0.37; 95% CI 
0.16–0.82; p = 0.014; Fig. 2). The total number of 
cardiovascular deaths, was also lower in the CoQ10 
group compared to the placebo group, 9 (8%) vs. 
21 (17%) corresponding to a relative reduction of 
51% (p = 0.052). From a Cox regression analysis 
stratified by center, the HR (CoQ10 vs. placebo) 
was 0.36 (95% CI 0.15–0.85; p = 0.020). Three 
(3%) patients were hospitalized due to worsening 
HF in the CoQ10 group vs. 16 (13%) patients in the 
placebo group (p = 0.007). The risk of unplanned 
hospitalization due to worsening HF counted as 
MACE was significantly lower in the CoQ10 group 
with a HR of 0.07 (95% CI 0.01–0.36; p = 0.001) us-
ing a Cox proportional hazards regression analysis 
stratified by center.
Adverse effects
There were no differences in the total number 
of adverse events in the CoQ10 group, 17 (16%) vs. 
28 (23%) in the placebo group (p = 0.188).
Comparison of the European population 
with the total population
Baseline patient characteristics and 
management. In comparison with the whole 
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population of  Q-SYMBIO, the Europeans 
were slightly older (mean 65 vs. 62 years), 
heavier (84.3 vs. 77.5 kg) with a lower heart 
rate (73 vs. 81 bpm), and a higher prevalence 
of atrial fibrillation (26% vs 18%) (Table 5). 
The majority of both populations were classified 
as NYHA class III (89% and 87%). Almost half as 
many of the European patients were classified as 
NYHA IV compared to the total population (5% 
vs. 9%). The lower percentage of patients with 
end-stage HF in the European population was in 
accordance with a greater average performance 
Table 1. Baseline characteristics of European patients.
Baseline characteristics Standard HF therapy + CoQ10 
(47%, n = 108)
Standard HF therapy + placebo 
(53%, n = 123)
Age [years] 65.7 ± 10 64.0 ± 12
Male gender* 90 (83%) 87 (71%)
Weight [kg] 83.7 ± 18 84.8 ± 18
BMI [kg/m2] 29 ± 5 29 ± 7
Heart rate [bpm] 72 ± 12 75 ± 12
Systolic BP [mmHg]* 127 ± 21 121 ± 19
Diastolic BP [mmHg] 77 ± 11 74 ± 11
Sinus rhythm 67 (62%) 77 (63%)
Atrial fibrillation 27 (25%) 32 (26%)
Rhythm, other (pace) 14 (13%) 14 (11%)
Ischemic heart disease 68 (63%) 84 (68%)
Dilated cardiomyopathy 35 (32%) 38 (31%)
Valvular heart disease 5 (5%) 1 (1%)
Duration of HF [months] 42 ± 59 39 ± 41
NYHA class II 6 (6%) 7 (6%)
NYHA class III 97 (90%) 109 (89%)
NYHA class IV 5 (5%) 7 (6%)
Left ventricular EF [%], [range] 33 ± 12 [10–65] 33 ± 12 [10–70]
Left ventricular EDD [mm] 64 ± 10 62 ± 11
Left ventricular ESD [mm] 51 ± 12 50 ± 13
6MWT [m], [range] 331 ± 91 [25–525] 321 ± 90 [90–490]
Serum CoQ10 [µg/mL]§ 0.95 ± 0.08 0.90 ± 0.07
NT-proBNP [pg/mL]§† 2470 ± 369, p50: 1208 2335 ± 398, p50: 1174
Use of medications:
ACEI/ARBs 99 (92%) 112 (91%)
Beta-blockers 94 (87%) 110 (89%)
Digoxin 35 (32%) 39 (32%)
Diuretics 90 (83%) 104 (85%)
Aldosterone antagonists 59 (55%) 66 (54%)
Statins 62 (57%) 69 (56%)
Anticoagulants 38 (35%) 48 (39%)
Diabetes medication 27 (25%) 32 (26%)
Device therapy:
Cardiac resynchronization device 2 5
Implanted cardioverter defibrillator 3 4
Values are mean ± standard deviation, number (percentage), mean ± standard deviation [range], mean ± standard deviation (median, p50), 
or number. §Values are mean ± standard error. †To convert values for NT-proBNP to picomoles per liter, divide by 8.457, *p = 0.03. ACEI/ARB 
— angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BMI — body mass index; BP — blood pressure CoQ10 — coenzyme 
Q10; EDD — end-diastolic diameter; ESD — end-systolic diameter; EF — ejection fraction; HF — heart failure; NT-proBNP — N-terminal  
pro–B-type natriuretic peptide; NYHA — New York Heart Association; 6MWT — 6-min walk test
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Table 2. Biochemical assessments at baseline at 3 months and 2 years.
Variable CoQ10 (mean ± SE)
3 months: n = 80
2 years: n = 40
Placebo (mean ± SE)
3 months: n= 88
2 years: n = 45
Serum CoQ10 [µg/mL]:
Baseline 0.95 ± 0.08 0.90 ± 0.07
3 months 3.42 ± 0.21* 0.82 ± 0.06
2 years 3.55 ± 0.34* 0.76 ± 0.04
Serum NT-proBNP [pg/mL]†
Baseline 2470 ± 369 2335 ± 398
3 months 2144 ± 370§ 2343 ± 418
2 years 1768 ± 375 2059 ± 390
*p < 0.001 vs. baseline, §p = 0.052 vs. baseline, †To convert values for NT-proBNP to picomoles per liter, divide by 8.457. CoQ10 — coenzyme Q10; 
NT-proBNP — N-terminal pro–B-type natriuretic peptide; SE — standard error
Table 3. Clinical and echocardiographic assessment changes from baseline.
Variable 3 months 2 years
CoQ10  
(n = 98)
Placebo  
(n = 109)
CoQ10  
(n = 81)
Placebo  
(n = 77)
NYHA classification:
Improvement 27 (28%) 26 (24%) 39 (48%)* 19 (25%)
Unchanged 68 (69%) 82 (75%) 42 (52%) 58 (75%)
Deterioration 3 (3%) 1 (1%) 1 (1%) 3 (4%)
VAS score (% ± SE):
Dyspnea –9.6 ± 2.4 –6.4 ± 2.3 NR NR
Fatigue –8.7 ± 2.6 –8.7 ± 2.1 NR NR
General symptoms change –7 ± 8.5 –7 ± 8.6 NR NR
6MWT [m] +25 ± 60 +20 ± 71 +19 ± 75 +2 ± 102
Heart rate [bpm] 0 (72 ± 15) 0 (74 ± 14) 0 (72 ± 13) –1 (73 ± 14)
Systolic BP [mmHg] 0 (127 ± 23) 0 (121 ± 18) 0 (127 ± 21) –3 (124 ± 20)
Diastolic BP [mmHg] –3 (74 ± 12) –1 (75 ± 12) 0 (74 ± 10) 0 (75 ± 11)
Left ventricular EF [%] +3 (36 ± 13) +1 (34 ± 12) +6 (39 ± 12)** +2 (35 ± 14)
Left ventricular EDD [mm] –2 (62 ± 10) 0 (62 ± 10) –1 (61 ± 9) –1 (61 ± 11)
Left ventricular ESD [mm] –2 (49 ± 11) –2 (48 ± 12) –2 (47 ± 13) 0 (48 ± 15)
Values given are ± standard deviation unless otherwise stated. *p = 0.003, **p = 0.021 for CoQ10 vs. placebo at 2 years, BP — blood pressure; 
CoQ10 — coenzyme Q10; EDD — end-diastolic diameter; EF — ejection fraction; ESD — end-systolic diameter; 6MWT — 6-min walk test;  
NR — not recorded; NYHA — New York Heart Association; SE — standard error; VAS — Visual Analogue Scale
Table 4. Major adverse cardiovascular events at 2 years.
Endpoint CoQ10 (n = 108) Placebo (n = 123)
Death due to MI 2 3
Death due to HF 1 6
Sudden cardiac death 4 8
Hospitalization due to acute HF and PE 0 1
Hospitalization due to worsening HF 3 15
Total 10 (9%)* 33 (27%)
*p = 0.001. CoQ10 — coenzyme Q10; HF — heart failure; MI — myocardial infarction; PE — pulmonary embolism
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in 6MWT (325 m vs. 287 m) and a slightly higher 
mean LVEF (33% vs. 31%). The Europeans were 
more frequently treated with beta-blockers (88% 
vs. 73%), statins (57% vs. 36%) and anticoagulants 
(37% vs. 25%). Patients treated with device-based 
therapy in Q-SYMBIO were all European. 
Event rate and treatment effects. The se-
rum CoQ10 levels and overall event rates in the CoQ10 
treated group of the European sub-population were 
similar or better than in the total population (Table 6). 
In the European sub-population, there was a significant 
improvement of 6% in LVEF compared to baseline 
(p = 0.021) in the CoQ10 group but no significant change 
in the placebo group (p = 0.234; Table 3). Whereas in 
the total population there were no significant between-
group differences or changes from baseline in any of 
the echocardiographic measurements [12].
Discussion
Summary
The beneficial effect of CoQ10 in the landmark 
Q-SYMBIO study of 420 international patients 
was reflected in the more racially homogeneous, 
more intensively treated subgroup of 231 European 
patients in terms of a significant improvement in 
NYHA class and a significant risk reduction for the 
primary composite MACE endpoint and reductions 
in the secondary endpoints of all-cause mortality, 
cardiovascular mortality and hospitalization for HF. 
The improvements in major clinical endpoints were 
supported by a significant increase in LVEF in the 
European population which had not been found in 
the larger cohort [12]. It was concluded that the 
therapeutic efficacy of CoQ10 demonstrated in the 
original Q-SYMBIO study was confirmed and even 
enhanced in the European sub-population.
Despite a careful selection of patients and an 
apparently homogenous population in clinical stud-
ies there are inherent hidden factors in HF trials 
that may affect outcomes. These factors include 
ethnicity, medical preferences of physicians, financ-
ing of medical care and drug availability [13–15, 19]. 
This study aimed to investigate if the therapeutic 
efficacy of CoQ10 found in a total international 
population of Q-SYMBIO (n = 420) also applied 
to a more homogeneous European sub-population 
(n = 231). Compared to the total population of 
Q-SYMBIO, the European sub-population was 
slightly older, with a lower heart rate, a higher 
LVEF and a higher percentage with atrial fibrilla-
tion. Similar differences in baseline characteristics 
have recently been found in trials of chronic HF 
(PARADIGM-HF, EMPHASIS-HF) and acute HF 
(ASCEND-HF, ASTRONAUT) with patients en-
rolled from 5–6 global regions including Asia and 
Europe [14, 16, 20]. The European sub-population of 
Q-SYMBIO showed a higher adherence to guide-
line recommended medical and device therapies 
when compared to the entire study population. The 
Europeans were more frequently prescribed beta-
blockers, statins and anticoagulants and less fre-
quently digoxin. Furthermore, all patients receiving 
device-based therapy in Q-SYMBIO were European.
Figure 1. Estimates of the time to primary endpoint 
of major adverse cardiovascular events (MACE) in the 
placebo group (solid line) and the coenzyme Q10 (CoQ10) 
group (dashed line). The primary endpoint was com-
posite MACE of hospital stay for worsening heart fail-
ure, cardiovascular death, mechanical support, or ur-
gent cardiac transplantation; CI — confidence interval; 
HR — hazard ratio.
Figure 2. Estimates of the secondary outcome death 
from any cause in the placebo group (solid line) and the 
coenzyme Q10 (CoQ10) group (dashed line); CI — confi-
dence interval; HR — hazard ratio.
152 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 2
A sub-optimal use of guideline-directed medi-
cal therapy in Asian countries compared to West-
ern countries has been described previously in 
registries for HF and recent large-scale HF trials 
[14, 20, 21]. Global differences in adherence to 
guideline-directed therapy in PARADIGM-HF and 
ASTRONAUT correspond to differences found 
in Q-SYMBIO including a higher rate in the pre-
scription of beta-blockers, anticoagulation and 
a lower rate of digoxin in European populations 
compared to Asian-Pacific populations [16, 20]. 
A lower use of lipid-lowering agents such as statins 
in Asian countries is also well known [22]. Simi-
larly, to Q-SYMBIO, analyses of PARADIGM-HF, 
ASTRONAUT and ASCEND-HF have demon-
strated a markedly lower use of device-based 
therapy in Asian-Pacific regions compared to other 
regions, probably reflecting economic differences 
[16, 20, 21]. The more frequent prescription of 
anti-coagulants reflects the higher occurrence of 
Table 5. Comparison of baseline characteristics in European and total population.
Characteristic European population  
(n = 231)
Total population  
(n = 420)
P
Age [years] 64.8 ± 11 62.2 ± 12 0.007 
Male sex 77% 73% 0.205
Weight [kg] 84.3 ± 17.8 77.5 ± 17 < 0.001
BMI [kg/m2] 28.9 ± 6 28 ± 6 0.049
Heart rate [bpm] 73 ± 12 81 ± 15 < 0.001 
Systolic BP [mmHg] 124 ± 20 123 ± 17 0.805 
Diastolic BP [mmHg] 75 ± 11 78 ± 11 < 0.001 
Sinus rhythm 62% 74% 0.003
Atrial fibrillation 26% 18% 0.019
Rhythm, other (pace) 12% 9% 0.138
Ischemic heart disease 66% 70% 0.333
Dilated cardiomyopathy 32% 27% 0.153
Valvular heart disease 3% 3% 1.000
Duration of HF [months] 41 ± 50 37 ± 41 0.271
NYHA class II 6% 3%
NYHA class III 89% 87% 0.077
NYHA class IV 5% 9%
Left ventricular EF [%], [range] 33 ± 12 [10–70] 31 ± 10 [10–70] 0.013
Left ventricular EDD [mm] 63 ± 11 65 ± 9 0.016
Left ventricular ESD [mm] 51 ± 13 54 ± 11 < 0.001
6MWT [m], [range] 325 ± 91 [25–525] 287 ± 98 [25–525] < 0.001
Serum CoQ10 [µg/mL] 0.92 ± 0.07 0.92 ± 0.05 0.211
NT-proBNP [pg/mL]† 2399 ± 272, p50: 1196 1783 ± 276, p50: 782 0.051
Use of medications:
ACEI/ARBs 91% 89% 0.476
Beta-blockers 88% 73% < 0.001
Digoxin 32% 45% 0.002
Diuretics 84% 79% 0.138
Aldosterone antagonists 54% 56% 0.934
Statin derivatives 57% 36% < 0.001
Anticoagulants 37% 25% 0.001
Diabetes treatment 26% 23% 0.441
Values are mean or number. †To convert values for NT-proBNP to picomoles per liter, divide by 8.457. ACE/ARB — angiotensin converting 
enzyme inhibitor/angiotensin receptor blocker; BMI — body-mass index; BP — blood pressure; CoQ10 — coenzyme Q10; EDD — end-diastolic 
diameter; ESD — end-systolic diameter; EF — ejection fraction; HF — heart failure; NT-proBNP — N-terminal pro–B-type natriuretic peptide; 
NYHA — New York Heart Association; 6MWT — 6-min walk test
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atrial fibrillation in the European sub-population of 
Q-SYMBIO. However, not all differences in medi-
cation can be explained by differences in baseline 
characteristics. Differences in medication and 
device therapy may be related to medical practice 
patterns, resources in medical care and perceptions 
of drug tolerability in Asian populations [21].
The findings in this analysis  showing no ma-
jor differences in outcomes in the European sub-
population despite differences in medical therapy 
and baseline characteristics were in accordance 
with PARADIGM-HF and EMPHASIS. In contrast, 
regional differences in outcome have been found in 
the acute HF trials ASTRONAUT and ASCEND-HF 
and may be a result of differences in the manage-
ment and duration of hospitalization for acute HF 
patients having a greater impact on outcome [14].
The serum level of CoQ10 in the CoQ10 treated Eu-
ropean sub-population remained constant and above 
3 μg/mL throughout the study period (Tables 2, 6). 
In contrast, the serum level of CoQ10 in CoQ10 
treated patients in the total population decreased 
from 3.01 ± 0.17 μg/mL at 3 months to 2.01 ± 0.20 
μg/mL at 2 years (Table 6). This could indicate 
a problem with compliance in the non-European 
patient population towards the end of the study 
period. The higher serum levels of CoQ10 of the 
European HF patients during the full study period 
may have contributed to the slightly increased 
CoQ10 efficacy (increased LVEF; Tables 3, 6) com-
pared with the efficacy found in the total population 
[12], despite the fact that the European cohort was 
better medicated and smaller sample size. 
Current drug therapy for HF predominately tar-
gets the secondary consequences of the failing heart 
by blocking overactivated neurohormonal pathways. 
While this therapy provides some relief of symp-
toms, improves prognosis and prevents some degree 
of cardiac remodeling, it does not target the basic 
energy depletion of the failing myocardium [23]. 
Significantly decreased tissue levels of CoQ10 have 
been found in patients with failing hearts such as 
dilated cardiomyopathy, restrictive cardiomyopathy 
and toxic myocardial disease [9]. In patients with HF 
of mixed etiology, a deficiency of CoQ10 in serum and 
tissue is more pronounced in the severest stages 
of HF. After oral supplementation with CoQ10 of 
selected patients with cardiomyopathy undergoing 
repeat biopsies after 5 months of treatment, tissue 
deficiency was reduced significantly and this was 
accompanied by an improvement in clinical and 
hemodynamic parameters [9, 10, 24]. The thera-
peutic efficacy of CoQ10 is primarily ascribed to its 
important role as electron carrier in the electron 
transport chain and strong anti-oxidative proper-
ties thus increasing bioenergetics and preventing 
oxidative damage of the failing myocardium [25, 26]. 
Other beneficial actions of CoQ10 include stabilization 
of cell membranes and the mitochondrial membrane 
transition pore thus protecting the myocardium from 
apoptotic events [27]. Further evidence suggests 
that endothelial function is improved [28, 29] and 
cardiac contractility increased by CoQ10 [30, 31]. 
In concert, these actions by CoQ10 may halt the 
vicious cycle of HF and protect the myocardium 
from further deterioration and perhaps facilitate 
a potential for myocardial recovery [32].
Limitations of the study
In comparing the European subgroup with 
the main Q-SYMBIO group it was not possible 
to ascribe differences between European vs. non-
-European to ethnic or geographic differences. 
The main Q-SYMBIO group of 420 included 231 
patients from Europe, 178 patients from Asia and 
11 patients from Australia. Thus, it was not possible 
in this subgroup analysis to elucidate ethnic differ-
ences but rather to study and confirm the efficacy 
of CoQ10 in a sub-group where standard therapy was 
more closely applied. The present study was not 
Table 6. Comparison of serum coenzyme Q10 (CoQ10) and overall event rates and risk reduction at  
2 years in the European and total population.
Endpoint European sub-population Total population
CoQ10  
(n = 108)
Placebo  
(n = 123)
RRR P CoQ10  
(n = 202)
Placebo  
(n = 218)
RRR P
CoQ10-S [µg/mL] 3.55 0.76 < 0.001 2.01 0.81 < 0.001
MACE 9% 27% 66% 0.001 15% 26% 43% 0.005
Death from any cause 9% 20% 53% 0.040 10% 18% 42% 0.036
Cardiovascular death 8% 17% 51% 0.052 9% 16% 43% 0.039
Hospitalization for HF 3% 13% 79% 0.007 8% 14% 41% 0.067 
HF — heart failure; MACE — major adverse cardiovascular events; RRR — relative risk reduction
154 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 2
powered to assess between-population differences. 
Measurements of LVEF have a varying intra- and 
interobserver variance from 3% to 7% depending 
on how trained the observer is, nevertheless, an 
absolute improvement of 6% in LVEF is likely to 
be genuine and clinically relevant. 
Conclusions
It was concluded that in the European subgroup 
of the Q-SYMBIO study the evidence of therapeutic 
efficacy of CoQ10 found in the original study was 
confirmed, despite higher adherence to guideline 
directed therapy than that of the whole group. 
In addition, CoQ10 therapy was associated with 
an increase in LVEF in the European population 
which had not been found in the larger cohort. This 
subgroup analysis provides confirmatory evidence 
for the conclusion of the original study that the 
treatment of patients with moderate to severe HF 
with CoQ10 in addition to standard therapy is safe, 
well tolerated and is associated with a reduction 
in symptoms, MACE and with improved survival.
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